The economics of preventive medicine face a critical test when genetic screening programs target diseases that manifest decades later. Universal cholesterol screening combined with genetic testing for familial hypercholesterolemia in children and young adults fails to meet standard cost-effectiveness benchmarks under current US healthcare economics, raising questions about how society values early intervention versus immediate resource allocation.
The analysis examined screening all pediatric patients for elevated LDL cholesterol followed by genetic testing for familial hypercholesterolemia mutations when levels exceed thresholds. Using the conventional $100,000 per quality-adjusted life-year standard and 3% annual discount rate, this approach does not achieve cost-effectiveness. The model incorporated treatment costs, genetic testing expenses, and projected cardiovascular benefits over patient lifetimes.
This finding illuminates a fundamental tension in precision medicine: genetic conditions with delayed manifestation often struggle to justify upfront screening costs when evaluated through traditional health economics frameworks. Familial hypercholesterolemia affects roughly 1 in 250 people, causing dramatically elevated cholesterol and early cardiovascular disease if untreated. Early identification enables decades of preventive statin therapy, potentially preventing heart attacks and strokes in patients' thirties and forties rather than standard care which typically begins treatment after symptoms emerge.
The discount rate emerged as the most influential variable, reflecting how economic models heavily weight immediate costs over distant benefits. This suggests that as healthcare systems evolve toward longer-term value assessments, genetic screening programs may become more economically attractive. The analysis represents incremental progress in quantifying prevention economics but underscores the challenge of justifying genetic medicine investments within current reimbursement structures.